Short Interest in Pharming Group (NASDAQ:PHAR) Decreases By 29.3%

Pharming Group (NASDAQ:PHAR) was the target of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 5,300 shares, a decrease of 29.3% from the January 31st total of 7,500 shares. Based on an average daily volume of 6,600 shares, the short-interest ratio is currently 0.8 days.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research report on Tuesday, December 17th. Jefferies Financial Group assumed coverage on shares of Pharming Group in a research report on Monday, December 9th. They issued a “buy” rating and a $14.00 price target for the company.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its stake in Pharming Group (NASDAQ:PHAR) by 16.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. Institutional investors own 0.03% of the company’s stock.

Pharming Group Trading Down 4.6 %

Shares of NASDAQ:PHAR traded down $0.42 during mid-day trading on Tuesday, hitting $8.73. The stock had a trading volume of 30,618 shares, compared to its average volume of 5,931. The company has a market cap of $593.91 million, a PE ratio of -33.58 and a beta of -0.10. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The company’s 50 day moving average is $9.29 and its 200-day moving average is $8.56. Pharming Group has a 12-month low of $6.65 and a 12-month high of $11.94.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.